Corvus Pharmaceuticals Inc

CRVSNASDAQ · USD
10.72USD+0.08 (+0.76%)
2210

Corvus Pharmaceuticals Inc (CRVS) Covered Calls

Corvus Pharmaceuticals Inc trades in the Biotechnology industry with an IV Rank of 15.87%, low versus the past year. CRVS's highest covered call setup is the $13.00 strike expiring Dec 18, 2026, sorted by theoretical annualized return. It's 22.18% out of the money with 35 days to expiration, a 22.65% return until expiration, and a 236.21% theoretical annualized return. Across the setups shown, annualized returns run from 93.74% to 236.21% at strikes between $12.00 and $30.00, with 35 to 434 days to expiration, as of Nov 13, 2026.

Read more

Running CRVS covered calls helps you generate income from Corvus Pharmaceuticals Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best CRVS covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If CRVS stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling CRVS covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given CRVS covered call is worth writing.

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer.

2026-12-183513.0022.180.051.75241.0022.65236.21-0.47+0.381181.70
2027-04-1615420.0087.970.101.40946.0088.91210.73-0.94+0.25111.30
2026-12-183512.0012.780.350.85171.0016.07167.60-3.29+0.37300.50
2028-01-2143430.00181.950.803.002016.00189.47159.35-7.52+0.386092.20
2027-04-1615417.0059.770.451.60681.0064.00151.70-4.23+0.333571.15
2028-01-2143427.00153.761.655.001801.00169.27142.36-15.51+0.53453.35
2027-04-1615416.0050.380.054.90541.0050.85120.51-0.47+0.511744.85
2027-04-1615415.0040.980.752.15511.0048.03113.83-7.05+0.422941.40
2028-01-2143420.0087.972.753.801211.00113.8295.72-25.85+0.561,5221.05
2028-01-2143422.00106.770.503.901186.00111.4793.74-4.70+0.44463.40

As of Nov 13, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank15.87% Low
  • Market cap (M$)898
  • 52 weeks high-60.52%
  • 52 weeks low66.51%
  • Analyst recommendationStrong Buy
    1.14
  • Target price$31.50
    193.84% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-05
  • P/E—
  • Future P/E—
  • EPS (ttm)-0.71
  • EPS growth next 5 years—

As of Nov 13, 2026